# A Case Report on Aplasia Cutis Congenita: Insights Into the Impact of Maternal Carbimazole Use

## TL;DR

A newborn with skin defects was linked to maternal use of carbimazole, highlighting the need for early diagnosis and multidisciplinary care in rare skin conditions.

## Contribution

This case report explores a potential association between maternal carbimazole use and congenital aplasia cutis.

## Key findings

- The newborn showed favorable recovery after receiving a dermo-epidermal allograft.
- No family history of similar cases was found, suggesting an external cause like carbimazole.
- Tailored wound care protocols were crucial for infection prevention and healing.

## Abstract

Congenital aplasia cutis (CAC) is a rare neonatal condition characterized by the absence of skin at birth, often associated with diverse underlying conditions. We report the case of a newborn male admitted on the second day of life with a skin defect on the anterior abdominal wall and a lesion on the left thigh. The mother was treated with carbimazole for hyperthyroidism. Notably, there were no similar cases in the family history. The patient showed favorable progress and normal development following a successful dermo-epidermal allograft. Particular attention was given to managing the risk of infection and ensuring optimal healing through tailored wound care protocols. This case underscores the complexity of CAC, highlighting the importance of early diagnosis, multidisciplinary care, and ongoing research to understand better and effectively treat this rare condition.